HomeNDC LookupIngredientsEconazole Nitrate › 51672-1303-08
Econazole Nitrate 10 mg/g Cream — NDC 51672-1303-08 package photo

Econazole Nitrate 10 mg/g Cream

by Sun Pharmaceutical Industries, Inc. · 1 TUBE in 1 CARTON (51672-1303-8) / 85 g in 1 TUBE
NDC 51672-1303-08
🏷️ FDA NDC (as labeled) 51672-1303-8 billing pads the package segment with a zero
This package
Contains85 g in 1 tube Cost per g$0.2144 NADAC Per package$18.22 / 85 g Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.3557/unit · Part D plans $0.4803/unit — full pricing hub ↓
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 51672-1303-8
Product NDC 51672-1303
11-digit billing NDC 51672130308
NCPDP billing unit GM — per gram (weight)
RxCUI 857366
UNII H438WYN10E
UPC 0351672130312
Application # ANDA076005
SPL Set ID 90c40d7f-94fa-440c-9815-30378f76ae79
Established class (EPC) Azole Antifungal
Chemical class Azoles
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2002-11-26
Route TOPICAL
Dosage form CREAM
Substance ECONAZOLE NITRATE
GPI-14 90154035103705
GPI class Econazole Nitrate
GCN Seq No 007371
GCN 30430
HICL code 016904
Ingredient (HICL) Econazole Nitrate
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 84:04.08.08
AHFS class Azoles (Skin And Mucous Membrane)
FDB label name ECONAZOLE NITRATE 1% CREAM
FDB brand name Econazole Nitrate
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 51672-1303-8 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 51672-1303-08. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Azole Antifungal class.

Pharmacologic class Azole Antifungal
Drug family (ATC) Imidazole and triazole derivatives, Imidazole derivatives
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerSun Pharmaceutical Industries, Inc.
Application holderSUN PHARMA CANADA INC
FDA applicationANDA076005 (ANDA)
Labeler code51672
First marketedNov 2002
Product typeHuman Prescription Drug
Portfolio889 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name ECONAZOLE NITRATE 1% CREAM Ingredient Econazole Nitrate
📖 What it is MedlinePlus · NLM

Econazole is used to treat skin infections such as athlete's foot, jock itch, and ringworm. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Econazole is an antifungal cream or foam that you apply to your skin to clear up fungal infections. Depending on which form you have, it can treat athlete's foot (the kind between...
  • Many people notice some relief fairly soon after starting treatment. That said, it's really important to keep going for the full course your doctor recommends — even if your skin l...
  • How long does it take to work, and how long do I need to use it?
  • Econazole is generally very well tolerated. The most common side effects are mild — a little burning, itching, or redness right where you apply it. Those were reported in less than...
📖 Read our full Econazole Topical guide →

Supplement & herbal interactions

Some supplements/herbs that may interact with Econazole Nitrate — tap one for details:

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII DRG3KJZ1TJ
    A plant-derived oil combined with polyethylene glycol to create a solubilizer. It helps dissolve or evenly distribute medicines in liquid formulations and improves how the body absorbs certain active ingredients.
  • UNII 8SKN0B0MIM
    Benzoic acid is a naturally occurring organic acid used as a preservative in medicines and foods. It helps prevent bacterial and fungal growth to extend shelf life and maintain product stability.
  • UNII 1P9D0Z171K
    BHT is a synthetic antioxidant that prevents fats and oils in medicines from breaking down and becoming rancid. It helps keep the product stable and effective during storage.
  • UNII 0324G66D0E
    Glycol stearate is a waxy compound made by combining stearic acid with ethylene glycol. It acts as an emulsifier and thickener, helping keep oil and water mixed together smoothly in liquid or semi-solid medicines.
  • UNII T5L8T28FGP
    Mineral oil is a clear, odorless liquid derived from crude oil. It acts as a lubricant and emollient in medications, helping pills slide smoothly during manufacturing and aiding moisture retention in topical products.
  • UNII 33GX5WQC0M
    PEG-32 stearate is a synthetic compound made by combining polyethylene glycol (PEG) with stearic acid. It acts as an emulsifier and surfactant to help mix oil and water-based ingredients, and may also serve as a solubilizer to improve how the active drug dissolves in the formulation.
  • UNII 8LQC57C6B0
    A synthetic compound made by combining polyethylene glycol with stearic acid. It acts as an emulsifier and surfactant to help mix oil and water-based ingredients together, and also serves as a thickener in creams and lotions.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

8 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.214 $18.22 / 85 g
Medicaid paysCMS SDUD · 12 mo $0.3557 $30.23 / 85 g
Medicare drug plans payPart D · Q2 2026 $0.4803 $40.83 / 85 g
NADAC price history (per g) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $0.238 $0.174
▲ Up 11% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Econazole Nitrate 10 mg/gthis 51672-1303-08 Sun 1 tube $0.214 AB Availability likely
Econazole Nitrate 10 mg/g 45802-0466-11 Padagis 1 tube $0.360 AB Availability likely +68%
Econazole Nitrate 10 mg/g 59651-0945-14 Aurobindo 1 tube AB FDA listed
Econazole Nitrate 10 mg/g 63629-8645-01 Bryant 1 tube AB FDA listed
Econazole Nitrate 10 mg/g 63629-8646-01 Bryant 1 tube AB FDA listed
Econazole Nitrate 10 mg/g 63629-8647-01 Bryant 1 tube AB FDA listed
Econazole Nitrate 10 mg/g 68788-8170-03 Preferred 1 tube AB FDA listed
Econazole Nitrate 10 mg/g 68788-8174-01 Preferred 1 tube AB FDA listed
Econazole Nitrate 10 mg/g 68788-8884-03 Preferred 1 tube AB FDA listed
Econazole Nitrate 10 mg/g 72162-1410-04 Bryant 1 tube AB FDA listed
Econazole Nitrate 10 mg/g 21922-0111-04 Encube 1 tube AB FDA listed
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2002
On the market since
Nov 2002
📍
2026
Currently FDA-listed
24 years listed
🔓
·
Generic on the market
this product is a generic
This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 51672-1303-08, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
3.7K
Units reimbursed last 4 qtrs
319.7K
Gross reimbursed last 4 qtrs
$113.7K
Avg / prescription
$30.90
Avg / unit
$0.3557
Latest quarter Q4 2025
973Rx
Medicaid pays / g
$0.3557
gross reimbursed
vs
NADAC / g
$0.2144
acquisition cost
=
Spread
+$0.1413
+66% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
46% FFS 54% MCO
Fee-for-service · 1,691 Rx Managed care · 1,989 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 2,890 units · 50.4 per 100k residents MN Wisconsin: no data reported WI Michigan: 6,545 units · 65.2 per 100k residents MI New York: 29,665 units · 152 per 100k residents NY Vermont: no data reported VT New Hampshire: 3,910 units · 279 per 100k residents NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 35,700 units · 284 per 100k residents IL Indiana: no data reported IN Ohio: 9,360 units · 79.4 per 100k residents OH Pennsylvania: 10,880 units · 83.9 per 100k residents PA New Jersey: no data reported NJ Massachusetts: 71,825 units · 1,026 per 100k residents MA California: 99,670 units · 256 per 100k residents CA Utah: 1,135 units · 33.2 per 100k residents UT Colorado: 680 units · 11.6 per 100k residents CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 4,335 units · 95.8 per 100k residents KY West Virginia: no data reported WV Virginia: 10,030 units · 115 per 100k residents VA Maryland: 9,125 units · 148 per 100k residents MD Connecticut: 2,295 units · 63.5 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: 935 units · 8.6 per 100k residents NC South Carolina: 1,360 units · 25.3 per 100k residents SC Delaware: no data reported DE Oklahoma: 880 units · 21.7 per 100k residents OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: 2,820 units · 55.2 per 100k residents AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 8,755 units · 28.7 per 100k residents TX Florida: 6,885 units · 30.5 per 100k residents FL
Units reimbursed · per 100k residents
8.61,026
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Massachusetts 1,026 /100k
2 Illinois 284 /100k
3 New Hampshire 279 /100k
4 California 256 /100k
5 New York 152 /100k
6 Maryland 148 /100k
7 Virginia 115 /100k
8 Kentucky 95.8 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube51672-1303-02 5,057 Rx · $109,091
1 tube this page51672-1303-08 3,680 Rx · $113,711
1 tube51672-1303-01 1,770 Rx · $31,920
Drug total (last 4 qtrs): 10,507 Rx · 559,732 units · $254,722 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Econazole Nitrate — the program that covers self-administered drugs. 3 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Econazole Nitrate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$1.65M
Claims incl. refills
37.4K
Beneficiaries
29.7K
Spend / beneficiary
$55.48
Spend / claim
$44.08
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Econazole Nitrate — the ingredient across all brands.

Top reported reactions

Fatigue60
Rash50
Dyspnoea47
Pain47
Nausea44
Diarrhoea42
Dizziness41

Age at onset

Adolescent1
Adult62
Elderly79

Reporter sex

919 reports
Male · 47%
Female · 53%
Unknown · 0%

Serious outcomes

Hospitalization331
Death53
Disabling26
Life-threatening23
Reports over time (by year) — tap or hover for the count & year
2025 2026 54 33
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
51672-1303-01 1 TUBE in 1 CARTON (51672-1303-1) / 15 g in 1 TUBE $0.3990 / g $5.98 2002-11-26 Active
51672-1303-02 1 TUBE in 1 CARTON (51672-1303-2) / 30 g in 1 TUBE $0.3604 / g $10.81 2002-11-26 Active
51672-1303-08 You're viewing this 1 TUBE in 1 CARTON (51672-1303-8) / 85 g in 1 TUBE $0.2144 / g $18.22 2002-11-26 Active

This pack has the lowest per-g cost of the 3 priced pack sizes ($0.2144 NADAC).

This pack accounts for about 35% of this product's recent Medicaid fills; the largest share goes to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in NDC 51672-1303-08?
NDC 51672-1303-08 is listed by the FDA — 1 tube in 1 carton / 85 g in 1 tube.
What NDC number is used to bill for this package of Econazole Nitrate 10 mg/g Cream?
Bill NDC 51672-1303-08 — the 11-digit billing format is 51672130308. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 52 words

INDICATIONS AND USAGE Econazole nitrate cream is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor.

⏱️ Dosage and Administration 122 words

DOSAGE AND ADMINISTRATION Sufficient econazole nitrate cream, 1%, should be applied to cover affected areas once daily in patients with tinea pedis, tinea cruris, tinea corporis, and tinea versicolor, and twice daily (morning and evening) in patients with cutaneous candidiasis. Early relief of symptoms is experienced by the majority of patients and clinical improvement may be seen fairly soon after treatment is begun; however, candidal infections and tinea cruris and corporis should be treated for two weeks and tinea pedis for one month in order to reduce the possibility of recurrence.

If a patient shows no clinical improvement after the treatment period, the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.

Contraindications 17 words

CONTRAINDICATIONS Econazole nitrate cream is contraindicated in individuals who have shown hypersensitivity to any of its ingredients.

⚠️ Warnings 9 words

WARNINGS Econazole nitrate cream is not for ophthalmic use.

🤒 Adverse Reactions 43 words

ADVERSE REACTIONS During clinical trials, approximately 3% of patients treated with econazole nitrate cream 1% reported side effects thought possibly to be due to the drug, consisting mainly of burning, itching, stinging and erythema. One case of pruritic rash has also been reported.

🔄 Drug Interactions 73 words

Drug Interactions Warfarin Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulation effect. Most cases reported product application with use under occlusion, genital application, or application to large body surface area which may increase the systemic absorption of econazole nitrate. Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.

🤰 Pregnancy 108 words

Pregnancy Econazole nitrate has not been shown to be teratogenic when administered orally to mice, rabbits or rats. Fetotoxic or embryotoxic effects were observed in Segment I oral studies with rats receiving 10 to 40 times the human dermal dose. Similar effects were observed in Segment II or Segment III studies with mice, rabbits and/or rats receiving oral doses 80 or 40 times the human dermal dose.

Econazole nitrate should be used in the first trimester of pregnancy only when the physician considers it essential to the welfare of the patient. The drug should be used during the second and third trimesters of pregnancy only if clearly needed.

🧓 Geriatric Use 84 words

Geriatric Use Clinical studies of econazole nitrate cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

🆘 Overdosage 36 words

OVERDOSE Overdosage of econazole nitrate in humans has not been reported to date. In mice, rats, guinea pigs and dogs, the oral LD 50 values were found to be 462, 668, 272, and >160 mg/kg, respectively.

🧬 Clinical Pharmacology 164 words

CLINICAL PHARMACOLOGY After topical application to the skin of normal subjects, systemic absorption of econazole nitrate is extremely low. Although most of the applied drug remains on the skin surface, drug concentrations were found in the stratum corneum, which, by far, exceeded the minimum inhibitory concentration for dermatophytes . Inhibitory concentrations were achieved in the epidermis and as deep as the middle region of the dermis.

Less than 1% of the applied dose was recovered in the urine and feces. Microbiology Econazole nitrate has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Dermatophytes Yeasts Epidermophyton floccosum Candida albicans Microsporum audouini Malassezia furfur Microsporum canis Microsporum gypseum Trichophyton mentagrophytes Trichophyton rubrum Trichophyton tonsurans Econazole nitrate exhibits broad-spectrum antifungal activity against the following organisms in vitro , but the clinical significance of these data is unknown .

Dermatophytes Yeasts Trichophyton verrucosum Candida guillermondii Candida parapsilosis Candida tropicalis

📦 How Supplied / Storage and Handling 37 words

HOW SUPPLIED Econazole Nitrate Cream, 1% is supplied in tubes of 15 g (NDC 51672-1303-1), 30 g (NDC 51672-1303-2) and 85 g (NDC 51672-1303-8). Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

📦 Storage and Handling 13 words

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

📋 Description 57 words

DESCRIPTION Econazole nitrate cream contains the antifungal agent, econazole nitrate USP 1%, in a water-miscible base consisting of benzoic acid, butylated hydroxytoluene, mineral oil, oleoyl polyoxylglycerides PEG-6-32 stearate/glycol stearate and purified water. The white to off-white soft cream is for topical use only. Chemically, econazole nitrate is 1-[2-{(4-chloro-phenyl) methoxy}-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole mononitrate.

Its structure is as follows: Chemical Structure

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.